Secretion of both IL-2 and IL-4 by tumor cells results in rejection and immunity

Journal of Immunotherapy

Volumn 19, Issue 1, 1996, Pages 21-32

  Strome, Scott E ^a   Chang, Alfred E ^a   Shu, Suyu ^b   Krauss, John C ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Immunogenicity; Interleukin 2; Interleukin 4

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CANCER TRANSPLANTATION; CONTROLLED STUDY; FEMALE; HOST RESISTANCE; IMMUNOGENICITY; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

EID: 0029984406     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199601000-00003     Document Type: Article

References (41)

1. Kedar E, Klein E. Cancer immunotherapy: are the results discouraging? Can they be improved? Adv Cancer Res 1992; 59:245-322.
2. Shu S, Strome SE, Krauss JC, Plautz GE, Chang AE. Tumor-draining lymph nodes as a source for generating therapeutic immune T cells. In: Chang AE, Shu S, eds. Immunotherapy of cancer with sensitized T lymphocytes. Austin, TX: RG Landes, 1994:1-14.
3. Prehn RT. Tumor immunogenicity: how far can it be pushed? Proc Natl Acad Sci USA 1993;90:4332-3.
4. LeGros G, Ben-Sasson SZ, Sede R, Finkelman FD, Paul WE. Generation of interleukin 4 (IL-4) producing cells in vivo and in vitro-IL-2 and IL-4 are required for in vitro generation of IL-4 producing cells. J Exp Med 1990,172: 921-9.
5. McGuire JL, Yang JA, Rothenberg EV. Influence of activating stimulus on functional phenotype: interleukin 2 mRNA accumulation differentially induced by ionophore and receptor ligands in subsets of murine T cells. Proc Natl Acad Sci USA 1988;85:6503-7.
6. Tairi S, Matsui M, Hayakawa K, Yokoyama T, Nariuchi H. Interleukin secretion by B cell lines and splenic B cells stimulated with calcium ionophore and phorbol ester. J Immunol 1987;139:2957-64.
7. Cantrell DA, Smith KA. Transient expression of IL-2 receptors: consequences for T cell growth. J Exp Med 1983; 158: 1895-911.
8. + subset in mice. Eur J Immunol 1988;12:2101-3.
9. Malkovsky M, Medawar PB, Thatcher DR, et al. Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin 2 or vitamin A acetate. Proc Natl Acad Sci USA 1985;82(2):536-8.
10. Ben-Sasson SZ, Le Gros G, Conrad DH, Finkelman FD, Paul WE. IL-4 production by T cells from naive donors: IL-2 is required for IL-4 production. J Immunol 1990; 145:1127-36.
11. Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin 4 deficient mice. Science 1991;254:707-10.
12. Swain SL, McKenzie DT, Weinberg AD, Hancock W. Characterization of T helper 1 and 2 subsets in normal mice: helper T cells responsible for IL-4 and IL-5 production are present as precursors that require priming before they develop into lymphokine-secreting cells. J Immunol 1988; 141: 3445-55.
13. Lee F, Yokota T, Otsuka T, et al. Isolation and characterization of a mouse interleukin cDNA clone that expresses B-cell stimulatory factor 1 activities and T-cell and mast cell stimulating activities. Proc Natl Acad Sci USA 1986; 83: 2061-5.
14. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
15. Mosman TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
16. Tepper RI, Mule JJ. Review: experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994;5:153-64.
17. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3613.
18. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12.
19. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanisms for the antitumor effect of Interleukin-4. Sci-ence 1992;257:548-51.
20. Gansbacher B, Zier K, Daniels B, Cronin K, Banneiji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990;172:1217-24.
21. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-16.
22. Strome SE, Krauss JC, Cameron MJ, Forslund K, Shu S, Chang AE. Immunobiologic effects of cytokine gene transfer of the B16-BL6 melanoma. Arch Otolaryngol Head Neck Surg 1993;119:1289-95.
23. Hart I. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 1979;97:587-600.
24. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
25. Danos O, Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 1988;85:6460-4.
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
27. Ohara J, Paul WE. Production of monoclonal antibody to and molecular characterization of B-cell stimulatory factor-1. Nature 1985;315:333-6.
28. Shu S, Chou T, Rosenberg SA. In vitro differentiation of T cells capable of mediating the regression of established tumors in mice. Cancer Res 1986;47:1354-69.
29. Gehan E. A generalized Wilcoxon test for comparing arbitrary single censored samples. Biometrika 1965;52:203-33.
30. Hock H, Dorsch M, Kunzendorf U, et al. Vaccinations with tumor cells genetically engineered to produce different cytokines: effectivity not superior to a classical adjuvant. Cancer Res 1993;53:714-16.
31. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-32.
32. Yang G, Hellstrom KE, Hellstrom I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995;154:2794-800.
33. Rosenberg SA, Terry WD. Passive immunotherapy of cancer in animals and man. Adv Cancer Res 1977;25:323-88.
34. + T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992; 149:3627-35.
35. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
36. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor a, granulocyte-macrophage colony-stimulating factor, and ▪y-interferon gene or admixed with conventional adjuvants. Cancer Res 1994;54:6022-6.
37. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleuin 7, tumor necrosis factor, or interferon 7. Proc Natl Acad Sci USA 1993;90:2774-8.
38. + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J Immunol 1994;153:5659-73.
39. Krauss JC, Strome SE, Change AE, Shu S. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4. J Immunother 1994;16:77-84.
40. Area MJ, Krauss JC, Aruga A, Cameron MJ, Chang AE. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete GM-CSF. Cancer Gene Ther 1996;3:39-47.
41. Chang AE, Shu S. Clinical science review: immunotherapy with sensitized lymphocytes. Cancer Invest 1992;5:357-69.